MetaVia to Present Innovative Cardiometabolic Research at 2026 ADA Scientific Sessions
- MetaVia will present innovative research on cardiometabolic diseases at the 2026 ADA Scientific Sessions, featuring three late-breaking abstracts.
- The focus includes DA-1726, a dual analog targeting GLP-1 and glucagon receptors to combat obesity.
- MetaVia aims to advance treatment options for metabolic diseases, with presentations set to be available online after the event.
MetaVia is set to showcase its innovative research in cardiometabolic diseases at the upcoming American Diabetes Association (ADA) Scientific Sessions in 2026, following the acceptance of three late-breaking abstracts for presentation. The company focuses on developing promising treatments, particularly with its candidate DA-1726, a novel dual oxyntomodulin analog targeting GLP-1 and glucagon receptors, designed to help tackle obesity. The leadership at MetaVia, including President and CEO Hyung Heon Kim, expresses confidence in their cardiometabolic portfolio, particularly as DA-1726 undergoes a Phase 1 Part 3 titration study expected to enhance tolerability at therapeutic doses, with results anticipated in Q4 2026.
Highlighting Key Research and Innovations
The first of the accepted abstracts highlights the safety and pharmacokinetics of DA-1726, presented by researcher Weikai 'Chris' Fang. This presentation aims to provide deeper insights into the efficacy of the drug and its application in clinical settings. Another abstract, led by Tae Hyoung Kim, investigates the effects of vanoglipel—a GPR119 agonist—when combined with Resmetirom in a diet-induced obese mouse model that simulates metabolic dysfunction-associated steatohepatitis (MASH). This study is crucial as it explores potential treatments for liver-related metabolic diseases.
Commitment to Cardiometabolic Health
Meanwhile, a third study led by Yuna Chae focuses on the combined effects of vanoglipel and Metformin on glycemic control and weight reduction, which are critical parameters for managing diabetes effectively. These presentations mark a significant milestone for MetaVia, demonstrating the company's commitment to advancing research in the field of cardiometabolic treatments.
Looking Ahead to ADA 2026
As the ADA Scientific Sessions approach, the anticipation for the insights these presentations will generate continues to grow, positioning MetaVia as a pivotal player in managing conditions such as obesity and metabolic diseases with innovative therapeutic approaches. All three posters will be publicly available on MetaVia’s website after the presentations, allowing greater access to their research findings.
Related Cashu News
Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…
Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…
Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…
Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…